Survival
CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma
Journal of Experimental & Clinical Cancer Research 2025 August 28 [Link] Federica Torricelli, Benedetta Donati, Veronica Manicardi, Mila Gugnoni, Francesca Reggiani, Gloria Manzotti, Pierluigi Di Chiaro, Cristian Ascione, Simonetta Piana, Riccardo Valli, Roberto Piro, Massimiliano Paci, Nicola Facciolongo, Filippo Lococo, Alessia Ciarrocchi Abstract Introduction: Diffuse Pleural Mesothelioma (DPM) is a rare and incurable cancer. Immune…
Read MorePrognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy
Immunotherapy 2025 August 20 [Link] Giulia Mazzaschi, Roberto Rosati, Simona D’Agnelli, Roberta Minari, Francesca Trentini, Prisca Tamarozzi, Martina Manini, Martina Zinelli Ronzoni, Alessandra Dodi, Letizia Gnetti, Lorena Bottarelli, Cinzia Azzoni, Gianmarco Martines, Monica Pluchino, Ilaria Toscani, Alessandro Leonetti, Fabiana Perrone, Paola Bordi, Giovanni Bocchialini, Luca Ampollini, Federico Quaini, Marcello Tiseo Abstract Aim: A translational multiscale…
Read MorePemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab
Lung Cancer 2025 September [Link] Sawana Ono, Hirokazu Taniguchi, Koji Kuroda, Teppei Hashimoto, Asuka Okada, Yasuhiro Goto, Hidenori Kitai, Yoichi Nakamura, Shinsuke Ogusu, Tetsunari Hase, Takayo Ota 10, Noriyuki Ebi, Makoto Furugen, Taishi Harada, Yoshiaki Kinoshita, Takaki Mizoguchi, Katsumi Nakatomi, Yoshifumi Soejima, Takahiro Yamada, Shinnosuke Takemoto, Hiroshi Mukae Abstract There is limited evidence regarding the…
Read MoreMolecular expression of glycosaminoglycans modifies the plasticity of biphasic mesothelioma in favor of tumor progression
Glycoconjugate Journal 2025 August 13 [Link] Camila Machado Baldavira, Aline Nery Qualiotto, Tabatha Gutierrez Prieto, Sandra de Morais Fernezlian, Aline Assato, Marcelo Balancin, Teresa Takagaki, Alexandre Ab’Saber, Ana Paula Pereira Velosa, Walcy Rosolia Teodoro, Vera Luiza Capelozzi Abstract The study aimed to verify whether the expression of glycosaminoglycans (GAGs) and proteoglycans (PGs) in the tumor…
Read MoreCo-Targeting Bcl-xL with Mcl-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Molecular Cancer Therapeutics 2025 August 14 [Link] R Taylor Ripley, Yuan Xu, Cristian G Medina, Deborah R Surman, Lacey E Dobrolecki, Monica Vilchis, Maheshwari Ramineni, Susan G Hilsenbeck, Yanming Li, Naren Li, Siqi Wu, Jaylon C Aggison, Xi Chen, Yi Zhu, Ying H Shen Abstract Diffuse mesothelioma (DM) is a rare but highly aggressive and…
Read MoreA Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value
Journal of Clinical Medicine 2025 August 4 [Link] Serkan Yaşar, Feride Yılmaz, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Zafer Arık 1, Şuayib Yalçın, Mustafa Erman Abstract Background: Pleural mesothelioma (PM) is a type of cancer that is difficult to diagnose and treat. Patients may have vastly varying prognoses, and prognostic factors may help guide the…
Read MoreInhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma
Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is an aggressive, asbestos-linked cancer with limited treatment options and a poor prognosis. Lactate dehydrogenase B (LDHB) converts lactate to pyruvate, and its silencing reduces mitochondrial…
Read MoreFirst-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study
Lung Cancer 2025 August 5 [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Daniel C Christoph 4, Frank Griesinger, Martin Reck, Petra Hoffknecht, Jonas Kuo, Nikolaj Frost, Christian Grohé, Martin Faehling, Jingting Luan, Julia Roeper, Paolo Chesi, Miriam Blasi, Martin Kimmich, Till Olchers, Helge Bischoff, Laura V Klotz, Inn Chung, Petros Christopoulos, Michael Thomas Abstract…
Read MoreTowards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications
Critical Reviews in Oncology/Hematology 2025 July 23 [Link] Paolo Ambrosini, Alessia Stanzi, Giuseppe Lo Russo, Piergiorgio Solli, Mario Occhipinti Abstract Pleural mesothelioma is a rare malignancy that has historically had a poor prognosis, even with systemic chemotherapy. Although immune checkpoint inhibitors have improved survival rates for patients with advanced, unresectable disease, their role in perioperative…
Read MoreA giant peritoneal mesothelioma extending to the pelvic floor: A case report and review of the literature
Journal of Cancer Research and Therapeutics 2025 April 1 [Link] Mathew Thomas, Harikrishnan Nandakumar, Parth Sampat, Stephen Graziano Abstract Malignant peritoneal mesothelioma (MPM) is a rare malignancy originating from the peritoneal serosa and is the second most common site of mesothelioma after the pleura. Localized disease presents as a focal circumscribed mass, whereas diffuse disease…
Read More
Skip to content